Max Homa Swings at Stigma, Partners on Seborrheic Dermatitis Campaign

WESTLAKE VILLAGE, CA – February 24, 2026 – Six-time PGA Tour winner Max Homa, a golfer known for his skill on the course and candid presence on social media, is now using his platform for a different kind of drive: raising public awareness for a chronic skin condition that affects an estimated 10 million Americans. Homa has joined Arcutis Biotherapeutics' “Free to Be Me” awareness campaign to discuss his personal, decades-long struggle with seborrheic dermatitis.

The partnership aims to destigmatize the condition, often mistaken for severe dandruff, and encourage individuals to move beyond over-the-counter remedies and “tee up a conversation” with their healthcare provider about long-term treatment options, including the company's steroid-free ZORYVE® (roflumilast) foam 0.3%.

A Personal Battle Beyond the Fairway

For years, while competing at the highest level of professional golf, Max Homa was fighting a private battle with his skin. He spent countless hours online, trying to self-diagnose the cause of his itchy, flaky, and red skin on his face and scalp. Like many, he cycled through numerous over-the-counter products that offered little to no lasting relief.

His story is the centerpiece of the new campaign, lending an authentic and relatable voice to a condition often hidden or misunderstood. “Even on the days when my face wasn’t red or flaky, seb derm was in the back of my mind—I’d catch myself wondering if other people could see it,” Homa shared in a statement. The psychological burden of a visible skin condition, especially for a public figure, was a constant concern. “I spent years trying different products, but without a diagnosis, nothing worked. Getting a proper diagnosis and treating my seb derm with ZORYVE made a big difference. Having clearer skin and scalp has allowed me to fully focus on what matters most to me.”

This strategy of leveraging a credible celebrity voice is a core component of Arcutis’s commercial playbook. The “Free to Be Me” campaign has previously featured actress Tori Spelling and, notably, NFL star Odell Beckham Jr., who also shared his experience with seborrheic dermatitis in early 2025. By consistently partnering with high-profile figures who have genuinely lived with these conditions, Arcutis aims to build trust and empower patients to seek the help they need.

Redefining Treatment for a Common Affliction

Seborrheic dermatitis is more than just a cosmetic issue. It is a chronic, recurrent inflammatory disease that can significantly diminish a person's quality of life. The condition causes persistent itching, redness, and flaking on areas of the body with oil-producing glands, most commonly the scalp, face, and chest.

“Many patients, like Max, spend years trying to self-diagnose or manage symptoms on their own, often assuming the problem is ‘just dandruff,’ not realizing their discomfort comes from a medical condition that can be effectively treated by a dermatologist,” said Dr. Tina Bhutani, a board-certified dermatologist and clinical researcher. Research supports this, with a 2022 survey indicating that 63% of sufferers did not believe their symptoms were serious enough to warrant medical attention, despite the condition’s negative impact on their daily lives.

For over two decades, the treatment landscape for seborrheic dermatitis remained largely stagnant, relying primarily on topical steroids and antifungals, which can have limitations for long-term use. “Because seb derm is lifelong, it’s essential to have effective, safe, and well-tolerated treatments for regular and long-term use,” Dr. Bhutani added. The introduction of ZORYVE foam represents the first new mechanism of action for the condition in more than 20 years, addressing a significant unmet need in dermatology.

ZORYVE's Rise in a Competitive Market

At the heart of the campaign is ZORYVE foam, a topical formulation of roflumilast, a targeted phosphodiesterase type 4 (PDE4) inhibitor. By inhibiting the PDE4 enzyme, the treatment reduces the production of pro-inflammatory mediators in the skin, calming inflammation and rebalancing the immune system. It is a once-daily, steroid-free, leave-in foam designed for use anywhere on the body, including hair-bearing areas like the scalp and beard.

The clinical data behind the treatment is compelling. In pivotal trials, 77% of individuals using ZORYVE foam achieved clear or almost clear skin after eight weeks, a significant improvement over the 53% who used an inactive foam. Furthermore, nearly 63% of patients experienced significant itch relief by week eight, with some reporting improvements in as little as 48 hours. Its most common side effects were mild, including the common cold, nausea, and headache.

This strong clinical profile has translated into commercial success and industry accolades. ZORYVE is now the number one prescribed branded topical therapy across its three approved indications: atopic dermatitis, plaque psoriasis, and seborrheic dermatitis. It has been recognized with an Allure “2025 Best of Beauty Breakthrough Award” and the National Psoriasis Foundation’s Seal of Recognition, underscoring its acceptance by both consumers and medical organizations.

The Business of Awareness

Arcutis Biotherapeutics is a commercial-stage company betting big on immuno-dermatology, and the Homa partnership is a key piece of its larger commercial strategy. With a strong gross margin of nearly 90% on its product and analyst peak sales estimates for ZORYVE reaching as high as $1.8 billion, the company is investing heavily in market education to realize that potential. Rather than relying on traditional direct-to-consumer advertising, Arcutis has opted for a more modern, narrative-driven approach.

The company’s high institutional ownership (98.4%) and a series of earnings beats over the past year signal investor confidence in its growth trajectory. The “Free to Be Me” campaign is more than a public service announcement; it is a strategic initiative designed to drive patient activation. By educating the public on the true nature of seborrheic dermatitis and providing a clear call to action—speak with a doctor—Arcutis is building the market for its innovative therapies from the ground up.

This collaboration showcases the evolving nature of pharmaceutical marketing, where authenticity and patient empowerment are becoming powerful tools for both public health and corporate growth. By linking a relatable public figure with a breakthrough treatment, Arcutis isn't just selling a product; it's aiming to fundamentally change the conversation around a condition that has long been misunderstood and undertreated.